| Dr Eric Christopher Kozfkay, DO | |
|
2147 Health Dr Sw Ste 100, Wyoming, MI 49519-9675 | |
| (616) 281-1600 | |
| (616) 281-2247 |
| Full Name | Dr Eric Christopher Kozfkay |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 20 Years |
| Location | 2147 Health Dr Sw Ste 100, Wyoming, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497710610 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Spectrum Health | Grand rapids, MI | Hospital |
| Metro Health Hospital | Wyoming, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Michigan Pain Consultants Pc | 8426959099 | 24 |
News Archive
Database enhancements developed at The Cancer Institute of New Jersey (CINJ) are helping physicians use technology to further ensure safety in the delivery of chemotherapy.
Researchers from Columbia University Medical Center's Herbert Irving Comprehensive Cancer Center have identified a protein that activates brain stem cells to make new neurons - but that may be hijacked later in life to cause brain cancer in humans. The protein called Huwe1 normally functions to eliminate other unnecessary proteins and was found to act as a tumor suppressor in brain cancer.
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.
› Verified 8 days ago
| Entity Name | Michigan Pain Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467418574 PECOS PAC ID: 8426959099 Enrollment ID: O20040225001094 |
News Archive
Database enhancements developed at The Cancer Institute of New Jersey (CINJ) are helping physicians use technology to further ensure safety in the delivery of chemotherapy.
Researchers from Columbia University Medical Center's Herbert Irving Comprehensive Cancer Center have identified a protein that activates brain stem cells to make new neurons - but that may be hijacked later in life to cause brain cancer in humans. The protein called Huwe1 normally functions to eliminate other unnecessary proteins and was found to act as a tumor suppressor in brain cancer.
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric Christopher Kozfkay, DO 5555 Glenwood Hills Pkwy Se Ste 2, Grand Rapids, MI 49512-2091 Ph: (616) 940-2662 | Dr Eric Christopher Kozfkay, DO 2147 Health Dr Sw Ste 100, Wyoming, MI 49519-9675 Ph: (616) 281-1600 |
News Archive
Database enhancements developed at The Cancer Institute of New Jersey (CINJ) are helping physicians use technology to further ensure safety in the delivery of chemotherapy.
Researchers from Columbia University Medical Center's Herbert Irving Comprehensive Cancer Center have identified a protein that activates brain stem cells to make new neurons - but that may be hijacked later in life to cause brain cancer in humans. The protein called Huwe1 normally functions to eliminate other unnecessary proteins and was found to act as a tumor suppressor in brain cancer.
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.
› Verified 8 days ago
Nicole Angela Strong, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2060 Health Dr Sw, Wyoming, MI 49519 Phone: 312-635-0973 | |
Mary Beth Kretschman, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 5900 Byron Center Ave Sw, Wyoming, MI 49519 Phone: 616-252-7199 | |
Dr. Colleen Michelle Sullivan, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 5838 Metro Way Sw, Wyoming, MI 49519 Phone: 616-249-5300 | |
Kristin Delooff, OTR/L Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 5900 Byron Center Ave Sw, Wyoming, MI 49519 Phone: 616-252-7199 | |
Dr. Julie A Gronek, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 5838 Metro Way Sw, Wyoming, MI 49519 Phone: 616-249-5300 |